Federal Trade Commission reverses decision on Illumina M&AApril 04, 2023 - " That brings the U.S. government position more in line with the sentiment of its European counterparts. Last Year, EU antitrust regulators had formally objected to Illumina’s pursuit of Grail, though an official divestment order has not yet been issued."
"The $8 billion acquisition deal closed in August 2021 before receiving a final sign-off from regulators. Illumina has maintained that it has kept Grail’s operations at an arms’ length."
https://www.fiercebiotech.com/medtech/ftc-reverses-course-orders-illumina-unravel-grail-buy
This reversal could have significant impact on Pfizer's bid to take-over Seagen for US$43 Billion with the FTC blocking the acquisition, as Merck (MSD) had experienced in an earlier attempt.
The FTC's decision on Illumina postively favors Pfizer's interest in ONCY's pelareorep given Pfizer's plans to develop its SC administered PD-(L)1 immune checkpoint inhibitor (sasanlimab)